PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic

PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, participated in an interview with Proactiveinvestors.com.

 

During the interview, Mr. Hadar discussed the advantages of PRF-110 to help tackle the opioid epidemic, including its ability to provide extended post-operative pain relief without the use of opioids, as well as the market potential for the product, and positive updates on the Company's ongoing Phase 3 clinical trial.

The interview can be viewed on Proactiveinvestors.com or on their YouTube channel:

https://www.youtube.com/@Proactive247